Ads
related to: aplastic anemia medications names- Patient Resources
Download Patient Resources
and Information.
- Recommended Dosage
Get Information on Dosing
and Administration.
- Possible Side Effects
Learn More About the
Possible Side Effects in LR-MDS.
- Official Patient Website
Visit Our Official Patient Website
for More Information.
- Patient Resources
helperwizard.com has been visited by 100K+ users in the past month
assistantsage.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
Aplastic anemia [2] (AA) [3] is a severe hematologic condition in which the body fails to make blood cells in sufficient numbers. Blood cells are produced in the bone marrow by stem cells that reside there. [4] Aplastic anemia causes a deficiency of all blood cell types: red blood cells, white blood cells, and platelets. [5] [6]
Anti-thymocyte globulin (ATG) is an infusion of horse or rabbit-derived antibodies against human T cells and their precursors , which is used in the prevention and treatment of acute rejection in organ transplantation and therapy of aplastic anemia due to bone marrow insufficiency.
Eltrombopag, sold under the brand name Promacta among others, is a medication used to treat thrombocytopenia (abnormally low platelet counts) and severe aplastic anemia. [3] [4] Eltrombopag is sold under the brand name Revolade outside the US and is marketed by Novartis. [6] It is a thrombopoietin receptor agonist. [3] It is taken by mouth. [3] [4]
This category reflects the organization of International Statistical Classification of Diseases and Related Health Problems, 10th Revision. Generally, diseases outlined within the ICD-10 codes D60-D61 within Chapter III: Diseases of the blood and blood-forming organs, and certain disorders involving the immune mechanism should be included in this category.
Hetrombopag (also known as rafutrombopag; trade name Hengqu) is a pharmaceutical drug for the treatment of thrombocytopenia and anemia. [1] [2] [3]It is a non-peptide small‐molecule thrombopoietin receptor agonist.
Many patients report increased alertness with the drug. Two rare but very serious effects include aplastic anemia and serious liver damage. The risk of aplastic anemia is between 1:3,600 and 1:5,000, of which 30% of cases are fatal. The risk of liver damage is between 1:24,000 to 1:34,000, of which 40% of cases are fatal. [citation needed]
Aplastic anemia is a condition where bone marrow does not produce sufficient new cells to replenish blood cells. [27] Autoimmune hemolytic anemia: D59.0-D59.1: Autoimmune hemolytic anemia (AIHA) is a type of hemolytic anemia where the body's immune system attacks its own red blood cells (RBCs), leading to their destruction .
Pure red cell aplasia (PRCA) or erythroblastopenia refers to a type of aplastic anemia affecting the precursors to red blood cells but usually not to white blood cells. In PRCA, the bone marrow ceases to produce red blood cells. There are multiple etiologies that can cause PRCA. The condition has been first described by Paul Kaznelson in 1922. [1]
Ads
related to: aplastic anemia medications nameshelperwizard.com has been visited by 100K+ users in the past month
assistantsage.com has been visited by 10K+ users in the past month